Dosing & Uses
Dosage Forms & Strengths
1-2 gtt of 1% solution in eye; may repeat in 5 minutes PRN; cycloplegia & mydriasis may last for 24 hours
Use 2% in heavily pigmented iris
Ocular: Flush eyes w/water
Ingestion: Emesis, lavage
Severe systemic ADR's: Physostigmine
Dosage Forms & Strengths
1-2 gtt of 0.5%, 1% or 2% solution in eye; may repeat 5 minutes later by second application of 0.5% or 1% solution if necessary
Frequency Not Defined
Burning sensation in eye
Raised intraocular pressure
Hyperreactive response in Down's syndrome children (atropine)
Hypersensitivity, untreated narrow angle glaucoma or increased IOP; untreated anatomically narrow angles
Sulfite sensitivity and other hypersensitivities; children with previous systemic reaction to atropine
Wait 5 min between drops
Transient elevatin in intraocular pressure may occur
Use caution in patients with Down syndrome (predisposed to angle-closure glaucoma)
Remove contact lenses prior to administration and wait 15 min before reinserting
The eldrely may be predisposed to increased intraocular pressure
The 2% solution may result in psychotic reactions and behavioral disturbances in children 30-45 min following instillation
Minimize absorption by using 1 drop of solution per eye and applying presure over the nasolacrimal sac for 2-3 min
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Onset: rapid; max effect not for 30 min
Mechanism of Action
Blocks action of acetylcholine resulting in relaxation of the cholinergically innervated iris sphincter muscle
Cholinergic stimulation of accommodative ciliary muscle of lens is also blocked
Anticholinergic effects of cyclopentolate in eye produce dilation of the pupil (mydriasis) and paralysis of accommodation (cycloplegia)
Onset of action: 25-75 min (cycloplegia); 30-60 min (mydriasis)
Duration: < 24hr
Absorption: Minimal systemic
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.